Skip to main content
Top

30-12-2023 | Lichen Planus | RESEARCH

MALT1 Protease Regulates T-Cell Immunity via the mTOR Pathway in Oral Lichen Planus

Authors: Xiao-Feng Wang, Fang Wang, Gang Zhou

Published in: Inflammation

Login to get access

Abstract

Oral lichen planus (OLP) is a T cell–mediated immune mucosal disease of unknown pathogenesis. Whether mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), an intracellular signaling protein, is involved in the T-cell immune dysfunction of OLP remains elusive. MALT1 expression in local and peripheral T cells of OLP and controls was analyzed using immunohistochemistry, multiplex immunohistochemistry, and flow cytometry. The expression of MALT1 in activated Jurkat T cells incubated with either OLP plasma or interleukin (IL)-7/IL-15 was determined by flow cytometry. The effects of MALT1 and mechanistic target of rapamycin (mTOR) on T-cell immunity were investigated through western blot, CCK8 assay, and flow cytometry. The expression of MALT1 protein was elevated in local OLP T cells and mucosal-associated invariant T (MAIT) cells, while reduced in peripheral OLP T cells, MAIT cells, and follicular helper-like MAIT (MAITfh) cells. Stimulation with OLP plasma and IL-7/ IL-15 had no effect on MALT1 expression in activated Jurkat T cells. MALT1 protease-specific inhibitor (MI-2) induced mTOR phosphorylation, increased B-cell lymphoma 10 (BCL10) expression, inhibited T-cell proliferation, and promoted T-cell apoptosis. The combination of MI-2 and rapamycin increased MALT1 expression, further suppressed T-cell proliferation, and facilitated T-cell apoptosis. MALT1 expression is aberrant in both local lesions and peripheral blood of OLP. Inhibition of the mTOR pathway further enhances the suppression of T-cell proliferation and the promotion of apoptosis induced by the MALT1 inhibitor MI-2.
Appendix
Available only for authorised users
Literature
21.
go back to reference Warnakulasuriya, S., O. Kujan, J.M. Aguirre-Urizar, J.V. Bagan, et al. 2021. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Diseases 27: 1862–1880. https://doi.org/10.1111/odi.13704.CrossRefPubMed Warnakulasuriya, S., O. Kujan, J.M. Aguirre-Urizar, J.V. Bagan, et al. 2021. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Diseases 27: 1862–1880. https://​doi.​org/​10.​1111/​odi.​13704.CrossRefPubMed
34.
37.
go back to reference Wang, C.J., Y.J. Li, J.N. Xue, H.S. Ci, et al. 2016. Correlation of Treg and IL-15 expression in the peripheral blood of patients with oral lichen planus. Shanghai Kou Qiang Yi Xue. 25: 438–442.PubMed Wang, C.J., Y.J. Li, J.N. Xue, H.S. Ci, et al. 2016. Correlation of Treg and IL-15 expression in the peripheral blood of patients with oral lichen planus. Shanghai Kou Qiang Yi Xue. 25: 438–442.PubMed
40.
go back to reference de Koning, H.D., D. Rodijk-Olthuis, I.M. van Vlijmen-Willems, L.A. Joosten, et al. 2010. A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: Upregulation of dectin-1 in psoriasis. The Journal of Investigative Dermatology 130: 2611–2620. https://doi.org/10.1038/jid.2010.196.CrossRefPubMed de Koning, H.D., D. Rodijk-Olthuis, I.M. van Vlijmen-Willems, L.A. Joosten, et al. 2010. A comprehensive analysis of pattern recognition receptors in normal and inflamed human epidermis: Upregulation of dectin-1 in psoriasis. The Journal of Investigative Dermatology 130: 2611–2620. https://​doi.​org/​10.​1038/​jid.​2010.​196.CrossRefPubMed
Metadata
Title
MALT1 Protease Regulates T-Cell Immunity via the mTOR Pathway in Oral Lichen Planus
Authors
Xiao-Feng Wang
Fang Wang
Gang Zhou
Publication date
30-12-2023
Publisher
Springer US
Published in
Inflammation
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-023-01952-w
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.